Fitting evolutionary process of matrix protein 2 family from influenza A virus using analytical solution of differential equation
- 1
- 2
- 3
Abstract
The evolution of protein family is a process along the time course, thus any mathematical methods that can describe a process over time could be possible to describe an evolutionary process. In our previously concept-initiated study, we attempted to use the differential equation to describe the evolution of hemagglutinins from influenza A viruses, and to discuss various issues related to the building of differential equation. In this study, we attempted not only to use the differential equation to describe the evolution of matrix protein 2 family from influenza A virus, but also to use the analytical solution to fit its evolutionary process. The results showed that the fitting was possible and workable. The fitted model parameters provided a way to further determine the evolutionary dynamics and kinetics, a way to more precisely predict the time of occurrence of mutation, and a way to figure out the interaction between protein family and its environment.
- S. Yan and G. Wu. (2009) Describing evolution of hemagglutinins from influenza A viruses using a differential equation, Protein Pept. Lett., 16, 794–804.
- G. Wu and S. Yan. (2002) Randomness in the primary structure of protein: Methods and implications, Mol. Biol. Today, 3, 55–69.
- G. Wu and S. Yan. (2006) Mutation trend of hemagglutinin of influenza A virus: A review from computational mutation viewpoint, Acta Pharmacol. Sin., 27, 513–526.
- G. Wu and S. Yan. (2006) Fate of influenza A virus proteins, Protein Pept. Lett., 13, 377–384.
- G. Wu and S. Yan. (2008) Lecture notes on computational mutation, Nova Science Publishers, New York.
- T. Betakova. (2007) M2 protein-a proton channel of influenza A virus, Curr. Pharm. Des., 13, 3231–3235.
- L. H. Pinto and R. A. Lamb. (2007) Controlling influenza virus replication by inhibiting its proton channel, Mol. Biosyst., 3, 18–23
- J. Beigel and M. Bray. (2008) Current and future antiviral therapy of severe seasonal and avian influenza, Antiviral Res., 78, 91–102.
- E. De Clercq and J. Neyts. (2007) Avian influenza A (H5N1) infection: Targets and strategies for chemotherapeutic intervention, Trends Pharmacol. Sci., 28, 280–285.
- F. Hayden. (2009) Developing new antiviral agents for influenza treatment: What does the future hold? Clin. Infect. Dis., 48, S3–S13.
- M. Schotsaert, M. De Filette, W. Fiers and X. Saelens. (2009) Universal M2 ectodomain-based influenza A vaccines: Preclinical and clinical developments, Expert Rev. Vaccines, 8, 499–508.
- Influenza virus resources, (2009) http://www.ncbi.nlm.nih.gov/genomes/FLU/Database/multiple.cgi.
- SPSS Inc., (2002) SigmaPlot for Windows, Version 8.02.
- G. Wu. (1996) Fit fluctuating blood drug concentration: A beginner’s first note, Pharmacol. Res., 33, 379–383.
- K. Yamaoka, T. Nakagawa and T. Uno. (1978) Application of Akaike’s information criterion (AIC) in the eva- luation of linear pharmacoketic equations, J. Pharmacokinet. Biopharm., 6, 165–175.
- G. Wu, P. Cossettini and M. Furlanut. (1996) Prediction of blood cyclosporine concentrations in haematological patients with multidrug resistance by one-, two- and three-compartment models using Bayesian and nonlinear least squares methods, Pharmacol. Res., 34, 47–57.